Prostate Cancer

Black men exhibit higher rates of prostate cancer for many complex reasons. This article explores both the social and genetic factors at play. Among all forms of cancer, prostate cancer displays the widest racial disparities, which persist at every stage that the cancer presents. This article, published in Prostate Cancer and Prostatic Diseases, analyzes these...

Given the troubled history of Black Americans in previous clinical studies, such as the Tuskegee syphilis study, it is not surprising that Black Americans may feel a sense of lingering mistrust in clinical trials and medical research. Despite the increased risk and aggressive nature of prostate cancer in Black patients compared to white patients, a...

The development and outcomes of prostate cancer can be significantly affected by multiple factors, such as genetic, socioeconomic, and environmental factors. Given this multifactorial approach to prostate cancer, disaggregating the available data on racial and ethnic subgroups is vital to pinpoint disparities in treatment status and diagnosis. In particular, Hispanic subpopulations with metastatic prostate cancer...

A lack of access to health care and treatment, brought about by socioeconomic and environmental factors, can impact the observed racial disparities in prostate cancer. While clinical trials open the doors to novel therapeutics targeted toward improving the survival of men with prostate cancer, an underrepresentation of racial groups could mean decreased insights into potential...

For advanced prostate cancer, androgen deprivation therapy (ADT) has been the cornerstone of systemic therapy. The most common treatment is testosterone suppression and bicalutamide, a nonsteroidal androgen receptor antagonist.  Enzalutamide is a second-generation androgen receptor inhibitor that inhibits nuclear translocation and DNA binding in prostate cancer cells, resulting in increased cytotoxicity. This study, published in JAMA...

A new analysis uncovers a racial paradox in prostate cancer care: While Black men are often diagnosed later and with more aggressive disease than white men, radiation therapy seems to work better for them than for their white peers. To come to that conclusion, researchers reviewed seven trials comprising more than 8,800 men with prostate...

A new imaging agent that detects prostate cancer that has spread to other parts of the body has been approved by the U.S. Food and Drug Administration. The tracer will help doctors find metastatic prostate cancer cells that are difficult to detect with traditional imaging methods, Michael Morris, M.D., a medical oncologist at Memorial Sloan...

In this MD Newsline exclusive interview with urologist Dr. Fenwa Milhouse, we discuss prostate cancer management challenges and disparities in the wake of the COVID-19 pandemic. MD Newsline: What are the biggest challenges that urologists are tasked with in the wake of COVID-19? Dr. Fenwa Milhouse: “COVID-19 has highlighted disparities that have existed. It’s magnified...

In this MD Newsline exclusive interview with urologist Dr. Fenwa Milhouse, we discuss recent research developments in the treatment of prostate cancer. We also discuss how to increase recruitment and enrollment of diverse groups in prostate cancer clinical trials. MD Newsline: Is there any research that excites you or that you think is important for healthcare...